Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

Osteocyte-Driven Downregulation of Snail Restrains Effects of Drd2 Inhibitors on Mammary Tumor Cells.

Liu S, Fan Y, Chen A, Jalali A, Minami K, Ogawa K, Nakshatri H, Li BY, Yokota H.

Cancer Res. 2018 May 16. pii: canres.0056.2018. doi: 10.1158/0008-5472.CAN-18-0056. [Epub ahead of print]

PMID:
29769195
2.

Dependence receptor UNC5A restricts luminal to basal breast cancer plasticity and metastasis.

Padua MB, Bhat-Nakshatri P, Anjanappa M, Prasad MS, Hao Y, Rao X, Liu S, Wan J, Liu Y, McElyea K, Jacobsen M, Sandusky G, Althouse S, Perkins S, Nakshatri H.

Breast Cancer Res. 2018 May 2;20(1):35. doi: 10.1186/s13058-018-0963-5.

3.

Attraction and Compaction of Migratory Breast Cancer Cells by Bone Matrix Proteins through Tumor-Osteocyte Interactions.

Chen A, Wang L, Liu S, Wang Y, Liu Y, Wang M, Nakshatri H, Li BY, Yokota H.

Sci Rep. 2018 Apr 3;8(1):5420. doi: 10.1038/s41598-018-23833-1.

4.

An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.

Pulliam N, Fang F, Ozes AR, Tang J, Adewuyi A, Keer H, Lyons J, Baylin SB, Matei D, Nakshatri H, Rassool FV, Miller KD, Nephew KP.

Clin Cancer Res. 2018 Apr 3. doi: 10.1158/1078-0432.CCR-18-0204. [Epub ahead of print]

PMID:
29615458
5.

Inhibiting checkpoint kinase 1 protects bone from bone resorption by mammary tumor in a mouse model.

Liu S, Liu Y, Minami K, Chen A, Wan Q, Yin Y, Gan L, Xu A, Matsuura N, Koizumi M, Liu Y, Na S, Li J, Nakshatri H, Li BY, Yokota H.

Oncotarget. 2018 Jan 19;9(10):9364-9378. doi: 10.18632/oncotarget.24286. eCollection 2018 Feb 6.

6.

A Spectrum Graph-Based Protein Sequence Filtering Algorithm for Proteoform Identification by Top-Down Mass Spectrometry.

Yang R, Zhu D, Kou Q, Bhat-Nakshatri P, Nakshatri H, Wu S, Liu X.

Proceedings (IEEE Int Conf Bioinformatics Biomed). 2017 Nov;2017:222-229. doi: 10.1109/BIBM.2017.8217653. Epub 2017 Dec 18.

PMID:
29503761
7.

Inflammation-associated microRNA changes in circulating exosomes of heart failure patients.

Beg F, Wang R, Saeed Z, Devaraj S, Masoor K, Nakshatri H.

BMC Res Notes. 2017 Dec 19;10(1):751. doi: 10.1186/s13104-017-3090-y.

8.

Mutational landscape of RNA-binding proteins in human cancers.

Neelamraju Y, Gonzalez-Perez A, Bhat-Nakshatri P, Nakshatri H, Janga SC.

RNA Biol. 2018 Jan 2;15(1):115-129. doi: 10.1080/15476286.2017.1391436. Epub 2017 Nov 14.

9.

Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer.

Wang R, Bhat-Nakshatri P, Padua MB, Prasad MS, Anjanappa M, Jacobson M, Finnearty C, Sefcsik V, McElyea K, Redmond R, Sandusky G, Penthala N, Crooks PA, Liu J, Zimmers T, Nakshatri H.

Mol Cancer Ther. 2017 Dec;16(12):2747-2758. doi: 10.1158/1535-7163.MCT-17-0717. Epub 2017 Oct 4.

10.

A system for detecting high impact-low frequency mutations in primary tumors and metastases.

Anjanappa M, Hao Y, Simpson ER, Bhat-Nakshatri P, Nelson JB, Tersey SA, Mirmira RG, Cohen-Gadol AA, Saadatzadeh MR, Li L, Fang F, Nephew KP, Miller KD, Liu Y, Nakshatri H.

Oncogene. 2018 Jan 11;37(2):185-196. doi: 10.1038/onc.2017.322. Epub 2017 Sep 11.

PMID:
28892047
11.

Reduction in Migratory Phenotype in a Metastasized Breast Cancer Cell Line via Downregulation of S100A4 and GRM3.

Chen A, Wang L, Li BY, Sherman J, Ryu JE, Hamamura K, Liu Y, Nakshatri H, Yokota H.

Sci Rep. 2017 Jun 14;7(1):3459. doi: 10.1038/s41598-017-03811-9.

12.

RareVar: A Framework for Detecting Low-Frequency Single-Nucleotide Variants.

Hao Y, Xuei X, Li L, Nakshatri H, Edenberg HJ, Liu Y.

J Comput Biol. 2017 Jul;24(7):637-646. doi: 10.1089/cmb.2017.0057. Epub 2017 May 25.

PMID:
28541743
13.

Inhibitory Effects of Dopamine Receptor D1 Agonist on Mammary Tumor and Bone Metastasis.

Minami K, Liu S, Liu Y, Chen A, Wan Q, Na S, Li BY, Matsuura N, Koizumi M, Yin Y, Gan L, Xu A, Li J, Nakshatri H, Yokota H.

Sci Rep. 2017 Apr 4;7:45686. doi: 10.1038/srep45686.

14.

Individualized Breast Cancer Characterization through Single-Cell Analysis of Tumor and Adjacent Normal Cells.

Anjanappa M, Cardoso A, Cheng L, Mohamad S, Gunawan A, Rice S, Dong Y, Li L, Sandusky GE, Srour EF, Nakshatri H.

Cancer Res. 2017 May 15;77(10):2759-2769. doi: 10.1158/0008-5472.CAN-16-3308. Epub 2017 Mar 1.

15.

Statistical modeling for sensitive detection of low-frequency single nucleotide variants.

Hao Y, Zhang P, Xuei X, Nakshatri H, Edenberg HJ, Li L, Liu Y.

BMC Genomics. 2016 Aug 22;17 Suppl 7:514. doi: 10.1186/s12864-016-2905-x.

16.

Molecular Insights of Pathways Resulting from Two Common PIK3CA Mutations in Breast Cancer.

Bhat-Nakshatri P, Goswami CP, Badve S, Magnani L, Lupien M, Nakshatri H.

Cancer Res. 2016 Jul 1;76(13):3989-4001. doi: 10.1158/0008-5472.CAN-15-3174. Epub 2016 Apr 25.

17.

Distinct Effects of Adipose-Derived Stem Cells and Adipocytes on Normal and Cancer Cell Hierarchy.

Anjanappa M, Burnett R, Zieger MA, Merfeld-Clauss S, Wooden W, March K, Tholpady S, Nakshatri H.

Mol Cancer Res. 2016 Jul;14(7):660-71. doi: 10.1158/1541-7786.MCR-16-0055. Epub 2016 Apr 20.

18.

Essential Components of Cancer Education.

Welch DR, Antalis TM, Burnstein K, Vona-Davis L, Jensen RA, Nakshatri H, Riegel AT, Spitz DR, Watson DK, Weiner GJ; Cancer Biology Training Consortium.

Cancer Res. 2015 Dec 15;75(24):5202-5. doi: 10.1158/0008-5472.CAN-15-2077. Epub 2015 Dec 1. Review.

19.

Ethnicity-Dependent and -Independent Heterogeneity in Healthy Normal Breast Hierarchy Impacts Tumor Characterization.

Nakshatri H, Anjanappa M, Bhat-Nakshatri P.

Sci Rep. 2015 Aug 27;5:13526. doi: 10.1038/srep13526.

20.

HOXB7 Is an ERα Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance.

Jin K, Park S, Teo WW, Korangath P, Cho SS, Yoshida T, Győrffy B, Goswami CP, Nakshatri H, Cruz LA, Zhou W, Ji H, Su Y, Ekram M, Wu Z, Zhu T, Polyak K, Sukumar S.

Cancer Discov. 2015 Sep;5(9):944-59. doi: 10.1158/2159-8290.CD-15-0090. Epub 2015 Jul 15.

21.

TFAP2C expression in breast cancer: correlation with overall survival beyond 10 years of initial diagnosis.

Perkins SM, Bales C, Vladislav T, Althouse S, Miller KD, Sandusky G, Badve S, Nakshatri H.

Breast Cancer Res Treat. 2015 Aug;152(3):519-31. doi: 10.1007/s10549-015-3492-2. Epub 2015 Jul 10.

22.

Organ-specific adaptive signaling pathway activation in metastatic breast cancer cells.

Burnett RM, Craven KE, Krishnamurthy P, Goswami CP, Badve S, Crooks P, Mathews WP, Bhat-Nakshatri P, Nakshatri H.

Oncotarget. 2015 May 20;6(14):12682-96.

23.

NF-κB-dependent and -independent epigenetic modulation using the novel anti-cancer agent DMAPT.

Nakshatri H, Appaiah HN, Anjanappa M, Gilley D, Tanaka H, Badve S, Crooks PA, Mathews W, Sweeney C, Bhat-Nakshatri P.

Cell Death Dis. 2015 Jan 22;6:e1608. doi: 10.1038/cddis.2014.569.

24.

PROGgeneV2: enhancements on the existing database.

Goswami CP, Nakshatri H.

BMC Cancer. 2014 Dec 17;14:970. doi: 10.1186/1471-2407-14-970.

25.

Cancer affects microRNA expression, release, and function in cardiac and skeletal muscle.

Chen D, Goswami CP, Burnett RM, Anjanappa M, Bhat-Nakshatri P, Muller W, Nakshatri H.

Cancer Res. 2014 Aug 15;74(16):4270-81. doi: 10.1158/0008-5472.CAN-13-2817. Epub 2014 Jun 30.

26.

The mushroom Ganoderma lucidum suppresses breast-to-lung cancer metastasis through the inhibition of pro-invasive genes.

Loganathan J, Jiang J, Smith A, Jedinak A, Thyagarajan-Sahu A, Sandusky GE, Nakshatri H, Sliva D.

Int J Oncol. 2014 Jun;44(6):2009-15. doi: 10.3892/ijo.2014.2375. Epub 2014 Apr 9.

27.

Angiopoietin-2 mediates blood-brain barrier impairment and colonization of triple-negative breast cancer cells in brain.

Avraham HK, Jiang S, Fu Y, Nakshatri H, Ovadia H, Avraham S.

J Pathol. 2014 Feb;232(3):369-81. doi: 10.1002/path.4304.

PMID:
24421076
28.

PROGgene: gene expression based survival analysis web application for multiple cancers.

Goswami CP, Nakshatri H.

J Clin Bioinforma. 2013 Oct 28;3(1):22. doi: 10.1186/2043-9113-3-22.

29.

Identification of FDA-approved drugs targeting breast cancer stem cells along with biomarkers of sensitivity.

Bhat-Nakshatri P, Goswami CP, Badve S, Sledge GW Jr, Nakshatri H.

Sci Rep. 2013;3:2530. doi: 10.1038/srep02530.

30.

ANTXR1, a stem cell-enriched functional biomarker, connects collagen signaling to cancer stem-like cells and metastasis in breast cancer.

Chen D, Bhat-Nakshatri P, Goswami C, Badve S, Nakshatri H.

Cancer Res. 2013 Sep 15;73(18):5821-33. doi: 10.1158/0008-5472.CAN-13-1080. Epub 2013 Jul 5.

31.

HOXB13 mediates tamoxifen resistance and invasiveness in human breast cancer by suppressing ERα and inducing IL-6 expression.

Shah N, Jin K, Cruz LA, Park S, Sadik H, Cho S, Goswami CP, Nakshatri H, Gupta R, Chang HY, Zhang Z, Cimino-Mathews A, Cope L, Umbricht C, Sukumar S.

Cancer Res. 2013 Sep 1;73(17):5449-58. doi: 10.1158/0008-5472.CAN-13-1178. Epub 2013 Jul 5.

32.

Interplay between estrogen receptor and AKT in estradiol-induced alternative splicing.

Bhat-Nakshatri P, Song EK, Collins NR, Uversky VN, Dunker AK, O'Malley BW, Geistlinger TR, Carroll JS, Brown M, Nakshatri H.

BMC Med Genomics. 2013 Jun 11;6:21. doi: 10.1186/1755-8794-6-21.

33.

PROGmiR: a tool for identifying prognostic miRNA biomarkers in multiple cancers using publicly available data.

Goswami CP, Nakshatri H.

J Clin Bioinforma. 2012 Dec 28;2(1):23. doi: 10.1186/2043-9113-2-23.

34.

Delivery of nanoparticles to brain metastases of breast cancer using a cellular Trojan horse.

Choi MR, Bardhan R, Stanton-Maxey KJ, Badve S, Nakshatri H, Stantz KM, Cao N, Halas NJ, Clare SE.

Cancer Nanotechnol. 2012 Dec;3(1-6):47-54. Epub 2012 Jul 20.

35.

Role of AKT isotypes in breast cancer.

Badve S, Nakshatri H.

J Pathol. 2013 Feb;229(3):e1. doi: 10.1002/path.4137. No abstract available.

PMID:
23132205
36.

Breast-cancer stem cells-beyond semantics.

Badve S, Nakshatri H.

Lancet Oncol. 2012 Jan;13(1):e43-8. doi: 10.1016/S1470-2045(11)70191-7. Review.

PMID:
22225725
37.

Biomarkers for breast cancer stem cells: the challenges ahead.

Gökmen-Polar Y, Nakshatri H, Badve S.

Biomark Med. 2011 Oct;5(5):661-71. doi: 10.2217/bmm.11.57. Review.

PMID:
22003917
38.

Persistent upregulation of U6:SNORD44 small RNA ratio in the serum of breast cancer patients.

Appaiah HN, Goswami CP, Mina LA, Badve S, Sledge GW Jr, Liu Y, Nakshatri H.

Breast Cancer Res. 2011 Sep 13;13(5):R86. doi: 10.1186/bcr2943.

39.

Virtual screening targeting the urokinase receptor, biochemical and cell-based studies, synthesis, pharmacokinetic characterization, and effect on breast tumor metastasis.

Wang F, Li J, Sinn AL, Knabe WE, Khanna M, Jo I, Silver JM, Oh K, Li L, Sandusky GE, Sledge GW, Nakshatri H, Jones DR, Pollok KE, Meroueh SO.

J Med Chem. 2011 Oct 27;54(20):7193-205. doi: 10.1021/jm200782y. Epub 2011 Oct 4.

40.

A large, consistent plasma proteomics data set from prospectively collected breast cancer patient and healthy volunteer samples.

Riley CP, Zhang X, Nakshatri H, Schneider B, Regnier FE, Adamec J, Buck C.

J Transl Med. 2011 May 27;9:80. doi: 10.1186/1479-5876-9-80.

41.

FOXA1 is an independent prognostic marker for ER-positive breast cancer.

Mehta RJ, Jain RK, Leung S, Choo J, Nielsen T, Huntsman D, Nakshatri H, Badve S.

Breast Cancer Res Treat. 2012 Feb;131(3):881-90. doi: 10.1007/s10549-011-1482-6. Epub 2011 Apr 19.

PMID:
21503684
42.

High-level expression of forkhead-box protein A1 in metastatic prostate cancer.

Jain RK, Mehta RJ, Nakshatri H, Idrees MT, Badve SS.

Histopathology. 2011 Apr;58(5):766-72. doi: 10.1111/j.1365-2559.2011.03796.x. Epub 2011 Mar 14.

PMID:
21401706
43.

Intrinsic subtype-associated changes in the plasma proteome in breast cancer.

Nakshatri H, Qi G, You J, Kerry B, Schneider B, Zon R, Buck C, Regnier F, Wang M.

Proteomics Clin Appl. 2009 Nov;3(11):1305-13. doi: 10.1002/prca.200900040.

PMID:
21136952
44.

Control of EVI-1 oncogene expression in metastatic breast cancer cells through microRNA miR-22.

Patel JB, Appaiah HN, Burnett RM, Bhat-Nakshatri P, Wang G, Mehta R, Badve S, Thomson MJ, Hammond S, Steeg P, Liu Y, Nakshatri H.

Oncogene. 2011 Mar 17;30(11):1290-301. doi: 10.1038/onc.2010.510. Epub 2010 Nov 8.

PMID:
21057539
45.
46.

SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD44+/CD24- phenotype.

Bhat-Nakshatri P, Appaiah H, Ballas C, Pick-Franke P, Goulet R Jr, Badve S, Srour EF, Nakshatri H.

BMC Cancer. 2010 Aug 6;10:411. doi: 10.1186/1471-2407-10-411.

47.

A water soluble parthenolide analog suppresses in vivo tumor growth of two tobacco-associated cancers, lung and bladder cancer, by targeting NF-κB and generating reactive oxygen species.

Shanmugam R, Kusumanchi P, Appaiah H, Cheng L, Crooks P, Neelakantan S, Peat T, Klaunig J, Matthews W, Nakshatri H, Sweeney CJ.

Int J Cancer. 2011 May 15;128(10):2481-94. doi: 10.1002/ijc.25587.

48.

ITF2 is a target of CXCR4 in MDA-MB-231 breast cancer cells and is associated with reduced survival in estrogen receptor-negative breast cancer.

Appaiah H, Bhat-Nakshatri P, Mehta R, Thorat M, Badve S, Nakshatri H.

Cancer Biol Ther. 2010 Sep 15;10(6):600-14. Epub 2010 Sep 4.

49.

Radiation resistance in breast cancer: are CD44+/CD24-/proteosome low/PKH26+ cells to blame?

Nakshatri H.

Breast Cancer Res. 2010;12(2):105. doi: 10.1186/bcr2559. Epub 2010 Apr 7.

50.

Subcellular localization of activated AKT in estrogen receptor- and progesterone receptor-expressing breast cancers: potential clinical implications.

Badve S, Collins NR, Bhat-Nakshatri P, Turbin D, Leung S, Thorat M, Dunn SE, Geistlinger TR, Carroll JS, Brown M, Bose S, Teitell MA, Nakshatri H.

Am J Pathol. 2010 May;176(5):2139-49. doi: 10.2353/ajpath.2010.090477. Epub 2010 Mar 12.

Supplemental Content

Loading ...
Support Center